✦ LIBER ✦

Randomised trial comparing zoladex∗ with nolvadex∗ plus zoladex in pre-menopausal advanced breast cancer

✍ Scribed by Kaufmann, M; Blamey, RW; Forbes, J; Jonat, W; Nordenskjold, B

Book ID: 123235226
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 303 KB
Volume: 1
Category: Article
ISSN: 0960-9776
DOI: 10.1016/0960-9776(92)90202-D

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Zoladex® plus tamoxifen versus zoladex®

Zoladex® plus tamoxifen versus zoladex® alone in pre- and peri-menopausal metastatic breast cancer

✍ Nicholson, R.I.; Walker, K.J.; McClelland, R.A.; Dixon, A.; Robertson, J.F.R.; B 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 536 KB

Multicenter randomized trial comparing z

Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update

✍ C. J. Tyrrell; J. E. Altwein; F. Klippel; E. Varenhorst; G. Lunglmayr; F. Boccar 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

A multicentre randomised trial comparing

A multicentre randomised trial comparing the LHRH agonist ‘Zoladex’ with ‘Zoladex’ in combination with flutamide in the treatment of advanced prostate cancer

📂 Article 📅 1990 🏛 Elsevier Science ⚖ 130 KB

A response in advanced post-menopausal b

A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist — Zoladex

✍ Cassano, A.; Astone, A.; Garufi, C.; Noviello, M.R.; Pietrantonio, F.; Barone, C 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 211 KB

A randomized trial comparing zoladex 3.6

A randomized trial comparing zoladex 3.6 mg depot with stilboestrol 3mg/day in advanced prostate cancer: Patient characteristics, response and treatment failures

✍ L.A. Emtage; C. Trethowan; C. Hilton; D.G. Arkell; D.M.A. Wallace; M.A. Hughes; 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 179 KB

A randomized trial comparing zoladex 3.6

A randomized trial comparing zoladex 3.6 mg depot with stilboestrol 3mg/day in advanced prostate cancer: Patient characteristics, response and treatment failures

✍ Trethowan, C.; Hilton, C.; Arkell, D.G.; Wallace, D..A.; Hughes, M.A.; Farrar, D 📂 Article 📅 1987 🏛 Elsevier Science ⚖ 141 KB